- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
MSN Pharma concludes USFDA audit with zero observations
Hyderabad: MSN Pharmaceuticals Inc. (MSNPI), a wholly-owned subsidiary of MSN Group of Companies, based out of Piscataway, New Jersey, USA has successfully completed its maiden USFDA audit with zero observations. The state-of-the-art finished dosages facility was established to bolster MSN Group's product portfolio as well as Contract Development & Manufacturing services, in the US...
Hyderabad: MSN Pharmaceuticals Inc. (MSNPI), a wholly-owned subsidiary of MSN Group of Companies, based out of Piscataway, New Jersey, USA has successfully completed its maiden USFDA audit with zero observations.
The state-of-the-art finished dosages facility was established to bolster MSN Group's product portfolio as well as Contract Development & Manufacturing services, in the US and several other key regulatory markets.
"This is a major accomplishment for us. It augments the core strategy of establishing ourselves as a preferred Contract Development & Manufacturing Service provider globally, offering endto-end drug manufacturing services. Also, besides helping us to deepen our presence in the US market, it will enable us to make high-quality generics affordable and accessible to the patients swiftly and efficiently," MSN Group commented.
Read also: MSN Labs gets USFDA nod for generic version of Cangrelor in India
Founded in 2003, MSN Group is the research-based pharmaceutical companies based out of Hyderabad, India. The organization presently has 16 state-of-the-art manufacturing facilities (twelve API and four finished dosage facilities) established across India and USA. The Group has an integrated R&D center for both API and formulation under one roof.
Read also: Dr Reddys, MSN Labs launch of generic Empagliflozin may lead to court battle
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751